<DOC>
	<DOCNO>NCT01505777</DOCNO>
	<brief_summary>The purpose study Evaluate Optimal Dosage Mosapride ( Medirac ) Probitics Irritable Bowel Syndrome Without Predominant Diarrhea .</brief_summary>
	<brief_title>Exploratory Clinical Study Evaluate Optimal Dosage Mosapride Probiotics Irritable Bowel Syndrome Without Predominant Diarrhea</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Mosapride</mesh_term>
	<criteria>Aged 1875 year satisfy RomeIII criterion diagnosis IBS Signed informed consent IBSD evidence cathartic colon history laxative abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>irritable bowel syndrome without predominant diarrhea</keyword>
	<keyword>Probiotics ( Medirac ) 10/mosapride 10mg</keyword>
	<keyword>Probiotics ( Medirac ) 15/mosapride 10mg</keyword>
	<keyword>Probiotics ( Medirac ) 15/mosapride 15mg</keyword>
	<keyword>Probiotics ( Medirac ) 30/mosapride 15mg</keyword>
	<keyword>Probiotics ( Medirac ) placebo/mosapride placebo</keyword>
</DOC>